| 5α-DHA | 5α-Androstane-3,17-dione |
| 5α-DHT | 5α-Dihydrotestosterone |
| 3α,5α-THA | Androsterone |
| 3β,5α-THA | Epiandrosterone |
| 3α,5β-THA | Etiocholanolone |
| 3α,5β-THA | Epietiocholanolone |
| 5-HT3 | Type-3 5-Hydroxytryptamine receptor (serotonin receptor) |
| 8-iso-PGF2α | 8-iso-Prostaglandin F2α |
| σ1R | σ1-Receptor |
| A | Androstenedione |
| AD | Androstanediol |
| ADIOL | Androstenediol |
| AKR1C1 | Aldo-keto reductase family 1 member C1 |
| AKR1C2 | Aldo-keto reductase family 1 member C2 |
| AKR1C3 | Aldo-keto reductase family 1 member C3 |
| AKR1D1 | 5β-Reductase |
| ALLO | 3α,5α-Tetrahydroprogesterone, allopregnanolone |
| AMPA | α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid |
| AMPAR | AMPA receptor |
| ANOVA | Analysis of variance |
| AT | Androstenetriol (5-androstene) |
| CI | Confidence interval |
| C | Conjugated steroid |
| C+U | Conjugated + unconjugated steroids |
| CLCN3 | Chloride voltage-gated channel 3 |
| CNS | Central nervous system |
| CYP11A1 | Cholesterol desmolase |
| CYP11B1 | 11β-Hydroxylase |
| CYP17A1 | C17-hydroxylase-C17,20-lyase |
| CYP19A1 | Aromatase |
| CYP21A2 | 21-Hydroxylase |
| CYP3A4 | Cytochrome P450 3A4 |
| CYP3A7 | Cytochrome P450 3A7 |
| CYP7B1 | 7α-hydroxylase |
| HSD3B1 | Type 1 3β-Hydroxysteroid dehydrogenase |
| HSD3B2 | Type 2 3β-Hydroxysteroid dehydrogenase |
| HSD3Bs | Type 1 and 2 3β-Hydroxysteroid dehydrogenases |
| HSD11B1 | Type 1 11β-Hydroxysteroid dehydrogenase |
| HSD11B2 | Type 2 11β-Hydroxysteroid dehydrogenase |
| HSD17B2 | Type 2 17β-Hydroxysteroid dehydrogenase |
| HSD17B3 | Type 3 17β-Hydroxysteroid dehydrogenase |
| HSD17B6 | Type 6 17β-Hydroxysteroid dehydrogenase (3α/β epimerase) |
| DHEA | Dehydroepiandrosterone |
| DHEAS | Dehydroepiandrosterone sulfate |
| DHP | Dihydroprogesterone |
| FEP | First-episode patient |
| GABA | γ-Aminobutyric acid |
| GABAAR | Type A γ-aminobutyric acid receptor |
| GC-MS/MS | Gas chromatography tandem mass spectrometry |
| HC | Healthy control |
| HPA | Hypothalamic-pituitary adrenal |
| IL-6 | Interleukin 6 |
| IL-17 | Interleukin 17 |
| L-type VGCC | L-type voltage gated calcium channels |
| LLR | Logarithm of likelihood ratio |
| LSD | Least significant difference |
| MC | LSD multiple comparisons |
| mRNA | Messenger ribonucleic acid |
| NAS | Neuroactive steroid |
| NMDAR | N-methyl-D-aspartate receptor |
| OPLS | Orthogonal predictions to latent structure |
| P | Progesterone |
| PD | Pregnanediol |
| PGF2α | Prostaglandin F2α |
| PNS | Peripheral nervous system |
| PREG | Pregnenolone |
| PREGS | Pregnenolone sulfate |
| PT | Pregnanetriol |
| ROS | Reactive oxygen species |
| SRD5A1 | Type 1 5α-reductase |
| SRD5A2 | Type 2 5α-reductase |
| SULT2A1 | Steroid sulfotransferase type 2A1 |
| STS | Steroid sulfatase |
| T | Testosterone |
| THP | Tetrahydroprogesterone |
| TNFα | Tumor necrosis factor α |
| TRPC5 | Short transient receptor potential channels 5 |
| TRPV1 | Vanilloid receptor |
| TRPM3 | Melastatin receptor |